Two grants will be awarded in 2023 to accelerate initiatives that are focused on improving access to precision oncology care and tackling inequalities for children with cancer around the world

The 2023 awards will be awarded to innovative programs tackling access to biomarker testing in the following cancer types:

Pediatric Cancers (solid tumours) that are known to harbor rare, actionable genomic alterations. Types of genomic alterations can include mutations (e.g., KRAS, BRAF, EGFR), gene fusions (e.g., ROS1, NTRK, FGFR, RET), and many more.

Apply for the Precision Oncology Patient Innovation Awards

View more details on how to apply

Next Important Date

Extended Deadline! June 30, 2023 – Deadline for initial applications

Submissions must be received no later than 12:00 AM (midnight) Eastern Standard Time

See all important dates and deadlines

Applications will be reviewed by an independent, non-Bayer review panel composed of experienced representatives from the clinical and patient advocacy communities.

Duration of Award: 1 Year

Award Value: Two awards in the amount of $50,000 USD each.

Find out more